Aarti Drugs Reports Q2 FY24-25 Profit Amidst Market Evaluation Adjustments

Aarti Drugs, a small-cap player in the pharmaceuticals and drugs industry, has recently undergone an adjustment in evaluation. This revision reflects the company's current market position and performance indicators, which have been influenced by various underlying trends.
In the second quarter of FY24-25, Aarti Drugs reported a profit after tax (PAT) of Rs 68.25 crore, which represents a notable change compared to previous periods. The return on capital employed (ROCE) has also been a focal point, currently standing at 12.85%. Additionally, the profit before tax (PBT) was recorded at Rs 44.40 crore, indicating shifts in profitability metrics.

Over the past five years, Aarti Drugs has shown modest growth, with net sales increasing at an annual rate of 6.68% and operating profit at 4.83%. However, the stock has been on a bearish trajectory, reflecting a decline of 7.4% since early January 2025. The company's performance has also lagged behind benchmark indices, with a return of -19.02% over the last year.

Despite these challenges, Aarti Drugs demonstrates strong management efficiency, highlighted by a ROCE of 18.89% and a low debt-to-EBITDA ratio of 1.56 times, suggesting a robust capacity to manage its debt obligations.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.